510(k) Report

510(k) · Cleared

Cleared

Accu-Chek Aviva Expert System

K142089510(k) TraditionalCleared Dec 17, 2014138-day reviewClass II21 CFR 862.1345

Data to Oct 25, 2026 (FDA decisions) Oct 12, 2026 (recalls) Sep 30, 2026 (MAUDE) refreshed weekly, last Nov 3, 2026

Roche Diagnostics Corporation · LFR Glucose Dehydrogenase, Glucose

Cleared on Dec 17, 2014 as substantially equivalent to K131366 (Roche Diagnostics Operations, Inc., 2013) after a 138-day review. Its family tree reaches back 6 generations to 2001.

Decided
Dec 17, 2014
Review
138 days
Class
Class II
Product code
LFR
Recalls
None
Predicates
1

Its longest line of descent runs back 6 generations to K010362 (2001). 12 ancestors in all. No later device cites it as a predicate yet.

  1. Root · 6 generations backK010362 Accu-Chek Comfort Curve Test StripRoche Diagnostics Corp. · 2001 · Recalled
  2. 5 generations backK043474 Accu-Chek Aviva SystemRoche Diagnostics Corp. · 2005 · Recalled
  3. 4 generations backK060620 Accu-Chek Aviva Test StripsRoche Diagnostics Corp. · 2006 · Recalled
  4. 3 generations backK101299 Accu-Chek Aviva Plus Blood Glucose Monitoring SystemRoche Diagnostics · 2011
  5. 2 generations backK111353 Accu-Check Combo SystemRoche Diagnostics · 2012 · Recalled
  6. 1 generation backK131366 Accu-Chek Aviva Expert Blood Glucose Monitoring SystemRoche Diagnostics Operations, Inc. · 2013
  7. This deviceK142089 Accu-Chek Aviva Expert SystemRoche Diagnostics Corporation · 2014
View FIG. 1 as a table

Line of descent and top descendants

GenerationNumberDeviceApplicantDecidedRecalls
−6K010362Accu-Chek Comfort Curve Test StripRoche Diagnostics Corp.20016
−5K043474Accu-Chek Aviva SystemRoche Diagnostics Corp.200510
−4K060620Accu-Chek Aviva Test StripsRoche Diagnostics Corp.20061
−3K101299Accu-Chek Aviva Plus Blood Glucose Monitoring SystemRoche Diagnostics2011—
−2K111353Accu-Check Combo SystemRoche Diagnostics20123
−1K131366Accu-Chek Aviva Expert Blood Glucose Monitoring SystemRoche Diagnostics Operations, Inc.2013—
0 (this device)K142089Accu-Chek Aviva Expert SystemRoche Diagnostics Corporation2014—

Other ancestors by year cleared

Year clearedDevicesWith a Class I recall
200330
200510
200610
200810
FIG. 1 — Lineage of K142089, 2001–2014Source: FDA 510(k) summaries, read by 510(k) Report · How lineage is built

Get the monthly Device Review Tracker

Notable FDA decisions, review times and new Class I recalls. See an issue.

Sources: FDA 510(k) database (decision fields), the FDA summary (predicates and indications), FDA recall and enforcement reports, and MAUDE; processed by 510(k) Report. Verify on FDA.gov · Methodology and accuracy.

Planning a device in LFR? A 510(k) Report weighs predicate choices, recall history and review times for a new device like this one.

  • Candidate predicates for a device like this, rankedin the report
  • Recall history across each candidate’s familyin the report
Get a 510(k) Report

What was it cleared against? (1)

Devices the submitter claimed this one is substantially equivalent to (*), and reference devices cited for a specific test or feature (†), as written in the FDA summary.

TypeNumberDeviceApplicantDecidedRecalls
*K131366Accu-Chek Aviva Expert Blood Glucose Monitoring System
Summary page 6
…age 6 === 3) Predicate device The predicate device for this submission is the ACCU-CHEK® Aviva Expert Blood Glucose Monitoring system, cleared in #k131366. Predicate Device Intended Use Statement: The ACCU-CHEK Aviva Expert System is indicated as an ai…
Roche Diagnostics Operations, Inc.2013—

What descends from it?

No later submission names this one as a predicate yet.

Has anything in its family been recalled? (0 Class I)

No FDA recall names this device.

No ancestor or descendant has a Class I recall.

What does this lineage say?

  • The line of descent spans 13 years and passes through 4 companies; a new generation was cleared every 1.3 years on median.
  • 8 of the 12 ancestors have a recall of any class.

How does its category compare?

All LFR devices

LFR Glucose Dehydrogenase, Glucose: FDA decisions, review times, recalls and adverse event reports over 20 years. 2014, this device’s year, is highlighted.

FDA decisions per year · LFR

1in 2015

2007: 12009: 12011: 62012: 132013: 32014: 32015: 1
2007high 13 (2012) · low 0 (2008)2026

2026 to Oct 25, outlined.

Median 510(k) review, days · LFR

161in 2014

2011: 296 days median2012: 152 days median2013: 212 days median2014: 161 days median
2007high 296 (2011) · low 152 (2012)2026

Receipt to decision; years with fewer than 3 clearances left blank.

Recalls per year · LFR

1in 2012

2007: 32008: 12009: 42011: 12012: 1
2007high 4 (2009) · low 0 (2010)2026

Class I (0 since 2007) Class II/III not classified

Adverse event reports per year · LFR

827in 2025

2007: 23,8192008: 6,5842009: 10,8232010: 4,8652011: 3,8022012: 3,3412013: 3,8212014: 3,9602015: 3,3662016: 2,1452017: 1032018: 1082019: 1082020: 1322021: 1642022: 1012023: 1032024: 1712025: 827
2007high 23,819 (2007) · low 101 (2022)2025

MAUDE reports naming product code LFR, not matched to any one device; reports are not rates.

View these four charts as a table
YearDecisionsMedian 510(k) review, daysRecalls (Class I)MAUDE reports
20071—323,819
20080—16,584
20091—410,823
20100—04,865
2011629613,802
20121315213,341
2013321203,821
2014316103,960
20151—03,366
20160—02,145
20170—0103
20180—0108
20190—0108
20200—0132
20210—0164
20220—0101
20230—0103
20240—0171
20250—0827
20260—0—

What is it indicated for?

The ACCU-CHEK Aviva Expert System is indicated as an aid in the treatment of insulin-requiring diabetes. The ACCU-CHEK Aviva Expert System consists of the ACCU-CHEK Aviva Expert Meter, ACCU-CHEK Aviva Plus test strips, ACCU-CHEK Aviva control solutions, and ACCU-CHEK Bolus Advisor. The ACCU-CHEK Aviva Expert System is intended to facilitate the optimization of glycemic control in patients who are trained in multiple daily insulin injection therapy and…

Read the full statement (341 words)

The ACCU-CHEK Aviva Expert System is indicated as an aid in the treatment of insulin-requiring diabetes. The ACCU-CHEK Aviva Expert System consists of the ACCU-CHEK Aviva Expert Meter, ACCU-CHEK Aviva Plus test strips, ACCU-CHEK Aviva control solutions, and ACCU-CHEK Bolus Advisor. The ACCU-CHEK Aviva Expert System is intended to facilitate the optimization of glycemic control in patients who are trained in multiple daily insulin injection therapy and are under the supervision of healthcare professionals experienced in managing insulin treated patients.

The ACCU-CHEK Aviva Expert blood glucose monitoring system is intended to be used for the quantitative measurement of glucose in fresh capillary whole blood samples drawn from the fingertips. The ACCU-CHEK Aviva Expert blood glucose monitoring system is intended for self-testing outside the body (in vitro diagnostic use) by people with diabetes. The ACCU-CHEK Aviva Expert blood glucose monitoring system is intended to be used by a single person and should not be shared. The ACCU-CHEK Aviva Expert blood glucose monitoring system should not be used for the diagnosis or screening of diabetes or for neonatal use. Alternative site testing should NOT be used with the ACCU-CHEK Aviva Expert blood glucose monitoring system. The ACCU-CHEK Aviva Expert System is intended for prescription home use only.

The ACCU-CHEK Aviva Expert meter is also indicated for the calculation of an insulin dose or carbohydrate intake based on user-entered data. The ACCU-CHEK Bolus Advisor, as a component of the Accu-Chek Aviva Expert meter, is intended for use in providing insulin dose recommendations in response to blood glucose, health events, and carbohydrate input. The ACCU-CHEK Bolus Advisor is intended to provide direction for insulin adjustment within the scope of a pre-planned treatment program from a healthcare professional. Before its use, a physician or healthcare professional must prescribe the ACCU-CHEK Aviva Expert System and provide the patient-specific target blood glucose, insulin-to-carbohydrate ratio, and insulin sensitivity parameters to be programmed into the ACCU-CHEK Bolus Advisor. Once programmed, a patient must consult with his/her physician or healthcare professional before making any changes to these ACCU-CHEK Bolus Advisor settings.

Indications for use read by OCR from a scanned FDA summary, so letters may be misread. Check the PDF before quoting it.

Cite this page

510(k) Report. “K142089: Accu-Chek Aviva Expert System.” Lineage record from FDA 510(k) data and the FDA summary. Updated Nov 3, 2026. Accessed Nov 6, 2026. https://510kreport.com/device/K142089

Report an extraction error

Tell us what is wrong; we check it against the FDA summary.

Are you the manufacturer?

Send a correction or an update to this page, for example a newer model or a public statement about a recall.

Record history
  • FDA decision record loaded May 2, 2026
  • Summary read Oct 13, 2026 (extraction version 9eaa42aa01ed)
  • Lineage and recalls computed Nov 3, 2026
  • Page last updated Nov 3, 2026